# Table 06 generation works with default values

    Code
      res
    Output
                                                                             A: Drug X    B: Placebo    C: Combination
      Event                                                                   (N=134)       (N=134)        (N=132)    
      ————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      SAE                                                                   104 (85.2%)   101 (82.1%)     99 (82.5%)  
        SAEs with fatal outcome                                             76 (62.3%)    70 (56.9%)      75 (62.5%)  
        Life-threatening SAEs                                                9 (7.4%)     13 (10.6%)      19 (15.8%)  
        SAEs requiring hospitalization                                      24 (19.7%)    28 (22.8%)      29 (24.2%)  
        SAEs resulting in substantial disruption of normal life functions   28 (23.0%)    21 (17.1%)      23 (19.2%)  
        Congenital anomaly or birth defect                                  26 (21.3%)    27 (22.0%)      20 (16.7%)  
        Other                                                               30 (24.6%)    37 (30.1%)      32 (26.7%)  
      AE leading to permanent discontinuation of study drug                 27 (22.1%)    26 (21.1%)      30 (25.0%)  
      AE leading to dose modification of study drug                         71 (58.2%)    86 (69.9%)      83 (69.2%)  
        AE leading to interruption of study drug                             4 (3.3%)      4 (3.3%)        3 (2.5%)   
        AE leading to reduction of study drug                               46 (37.7%)    46 (37.4%)      51 (42.5%)  
        AE leading to dose delay of study drug                              20 (16.4%)    28 (22.8%)      30 (25.0%)  
        Other                                                               34 (27.9%)    48 (39.0%)      46 (38.3%)  
      Any AE                                                                122 (91.0%)   123 (91.8%)    120 (90.9%)  
        MILD                                                                 7 (5.2%)      9 (6.7%)        4 (3.0%)   
        MODERATE                                                            24 (17.9%)    24 (17.9%)      23 (17.4%)  
        SEVERE                                                              91 (67.9%)    90 (67.2%)      93 (70.5%)  

# Table 06 generation works with custom values

    Code
      res
    Output
      Table 6. Overview of Adverse Events(1), Safety Population, Pooled Analyses(2)
      
      ——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
                                                                             A: Drug X    B: Placebo    C: Combination      Total   
      Event                                                                   (N=134)       (N=134)        (N=132)         (N=400)  
      ——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      SAE                                                                   104 (85.2%)   101 (82.1%)     99 (82.5%)     304 (83.3%)
        SAEs with fatal outcome                                             76 (62.3%)    70 (56.9%)      75 (62.5%)     221 (60.5%)
        Life-threatening SAEs                                                9 (7.4%)     13 (10.6%)      19 (15.8%)     41 (11.2%) 
        SAEs requiring hospitalization                                      24 (19.7%)    28 (22.8%)      29 (24.2%)     81 (22.2%) 
        SAEs resulting in substantial disruption of normal life functions   28 (23.0%)    21 (17.1%)      23 (19.2%)     72 (19.7%) 
        Congenital anomaly or birth defect                                  26 (21.3%)    27 (22.0%)      20 (16.7%)     73 (20.0%) 
        Other                                                               30 (24.6%)    37 (30.1%)      32 (26.7%)     99 (27.1%) 
      AE leading to permanent discontinuation of study drug                 27 (22.1%)    26 (21.1%)      30 (25.0%)     83 (22.7%) 
      AE leading to dose modification of study drug                         71 (58.2%)    86 (69.9%)      83 (69.2%)     240 (65.8%)
        AE leading to interruption of study drug                             4 (3.3%)      4 (3.3%)        3 (2.5%)       11 (3.0%) 
        AE leading to reduction of study drug                               46 (37.7%)    46 (37.4%)      51 (42.5%)     143 (39.2%)
        AE leading to dose delay of study drug                              20 (16.4%)    28 (22.8%)      30 (25.0%)     78 (21.4%) 
        Other                                                               34 (27.9%)    48 (39.0%)      46 (38.3%)     128 (35.1%)
      Any AE {1}                                                            122 (91.0%)   123 (91.8%)    120 (90.9%)     365 (91.2%)
        MILD                                                                 7 (5.2%)      9 (6.7%)        4 (3.0%)       20 (5.0%) 
        MODERATE                                                            24 (17.9%)    24 (17.9%)      23 (17.4%)     71 (17.8%) 
        SEVERE                                                              91 (67.9%)    90 (67.2%)      93 (70.5%)     274 (68.5%)
      ——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      
      {1} - Severity as assessed by the investigator
      ——————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      
      Source: [include Applicant source, datasets and/or software tools used].
      (1) Treatment-emergent AE defined as [definition]. MedDRA version X.
      (2) Duration = [e.g., X-week double-blind treatment period or, median and a range indicating
      pooled trial durations].
      
      Abbreviations: AE, adverse event; CI, confidence interval; MedDRA, Medical Dictionary for
      Regulatory Activities; N, number of patients in treatment arm;
      n, number of patients with at least one event; SAE, serious adverse event

# Table 06 generation works with risk difference column

    Code
      res
    Output
                                                                             A: Drug X    B: Placebo    C: Combination   Risk Difference (%) (95% CI)
      Event                                                                   (N=134)       (N=134)        (N=132)                 (N=268)           
      ———————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————————
      SAE                                                                   104 (77.6%)   101 (75.4%)     99 (75.0%)          -2.2 (-12.4 - 7.9)     
        SAEs with fatal outcome                                             76 (56.7%)    70 (52.2%)      75 (56.8%)          -4.5 (-16.4 - 7.4)     
        Life-threatening SAEs                                                9 (6.7%)      13 (9.7%)      19 (14.4%)           3.0 (-3.6 - 9.5)      
        SAEs requiring hospitalization                                      24 (17.9%)    28 (20.9%)      29 (22.0%)          3.0 (-6.5 - 12.4)      
        SAEs resulting in substantial disruption of normal life functions   28 (20.9%)    21 (15.7%)      23 (17.4%)          -5.2 (-14.5 - 4.0)     
        Congenital anomaly or birth defect                                  26 (19.4%)    27 (20.1%)      20 (15.2%)          0.7 (-8.8 - 10.3)      
        Other                                                               30 (22.4%)    37 (27.6%)      32 (24.2%)          5.2 (-5.1 - 15.6)      
      AE leading to permanent discontinuation of study drug                 27 (20.1%)    26 (19.4%)      30 (22.7%)          -0.7 (-10.3 - 8.8)     
      AE leading to dose modification of study drug                         71 (53.0%)    86 (64.2%)      83 (62.9%)          11.2 (-0.5 - 22.9)     
        AE leading to interruption of study drug                             4 (3.0%)      4 (3.0%)        3 (2.3%)            0.0 (-4.1 - 4.1)      
        AE leading to reduction of study drug                               46 (34.3%)    46 (34.3%)      51 (38.6%)          0.0 (-11.4 - 11.4)     
        AE leading to dose delay of study drug                              20 (14.9%)    28 (20.9%)      30 (22.7%)          6.0 (-3.2 - 15.1)      
        Other                                                               34 (25.4%)    48 (35.8%)      46 (34.8%)          10.4 (-0.5 - 21.4)     
      Any AE                                                                122 (91.0%)   123 (91.8%)    120 (90.9%)           0.7 (-6.0 - 7.5)      
        MILD                                                                 7 (5.2%)      9 (6.7%)        4 (3.0%)            1.5 (-4.2 - 7.2)      
        MODERATE                                                            24 (17.9%)    24 (17.9%)      23 (17.4%)           0.0 (-9.2 - 9.2)      
        SEVERE                                                              91 (67.9%)    90 (67.2%)      93 (70.5%)         -0.7 (-12.0 - 10.5)     

